金达威(002626) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥927,635,231.69, a decrease of 3.40% compared to the same period last year[4] - Net profit attributable to shareholders was ¥158,552,126.11, down 47.07% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥179,909,643.43, a decrease of 39.21% compared to the previous year[4] - The basic earnings per share decreased by 46.94% to ¥0.26[4] - The net profit for Q3 2021 was approximately ¥661.81 million, a decrease of 18.3% compared to ¥809.72 million in the same period last year[30] - The company's operating profit for Q3 2021 was approximately ¥791.89 million, down 18.5% from ¥972.29 million in the same quarter last year[33] - The total comprehensive income for Q3 2021 was approximately ¥685.69 million, compared to ¥757.56 million in the same quarter last year, a decrease of 9.5%[30] - The company's tax expenses for Q3 2021 were approximately ¥119.39 million, down from ¥176.30 million in the previous year, a reduction of 32.3%[33] Assets and Liabilities - The total assets increased by 9.71% to ¥5,652,896,874.38 compared to the end of the previous year[5] - The total liabilities amounted to ¥1,840,922,445.78, compared to ¥1,660,372,379.98 at the end of 2020, reflecting an increase of about 10.87%[25] - The total equity attributable to shareholders reached ¥3,751,256,075.04, up from ¥3,428,400,989.49, indicating a growth of approximately 9.43%[25] - The company's long-term borrowings increased to ¥641,676,945.01 from ¥400,473,872.81, representing a significant rise of approximately 60.06%[23] - The company's total liabilities were CNY 2,093,572,650.29, reflecting a stable financial position despite the challenges faced[40] - The company has a total of ¥21.99 million in contract liabilities, indicating future revenue obligations[44] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥639,538,411.01, down 14.08% year-on-year[4] - The company recorded a net cash outflow from investment activities of approximately ¥266.08 million, a decline of 200.45% year-on-year[11] - Cash inflow from financing activities rose by 218.60% to approximately ¥367.04 million, driven by an increase in borrowed funds[11] - The net cash flow from operating activities for Q3 2021 was CNY 639,538,411.01, a decrease of 14.1% compared to CNY 744,335,603.38 in Q3 2020[35] - The total cash outflow from investing activities was CNY 269,933,898.43, compared to CNY 882,958,374.26 in the previous year, indicating a significant reduction in investment spending[35] - The net cash flow from financing activities was -CNY 447,842,583.78, an improvement from -CNY 784,340,424.86 in Q3 2020, reflecting better management of financing costs[37] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 43,158[14] - The largest shareholder, Xiamen Jindawei Investment Co., Ltd., holds a 34.34% stake, amounting to 211,712,732 shares[14] Operational Highlights - Operating income decreased by 86.35% to approximately ¥2.25 million, primarily due to a reduction in government subsidies[11] - The company reported a significant increase in long-term borrowings by 60.23% to ¥641,676,945.01[9] - The company plans to expand its production capacity with investments in new projects, including 800 tons of Vitamin A oil and 200 tons of Vitamin D3 oil[11] - The company reported a decrease in sales prices for coenzyme Q10 and vitamin A, alongside an increase in raw material costs, impacting profitability[18] Inventory and Costs - Total operating costs rose to ¥1,897,733,231.84, up from ¥1,659,482,637.36, indicating an increase of approximately 14.36%[26] - Inventory as of September 30, 2021, was ¥786,326,190.08, compared to ¥690,065,656.34 at the end of 2020, marking an increase of about 13.93%[21] - The company's inventory stood at CNY 690,065,656.34, remaining stable compared to previous periods, indicating effective inventory management[40] Research and Development - Research and development expenses rose to approximately ¥55.75 million, an increase of 13.1% from ¥49.21 million in the previous year[33]